Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.360 USD | +3.88% |
|
-17.67% | -10.96% |
Feb. 05 | Sector Update: Health Care Stocks Higher Late Afternoon | MT |
Feb. 05 | Acrivon Therapeutics Says FDA Grants its ACR-368 OncoSignature Assay Breakthrough Device Designation | MT |
Capitalization | 167M 160M 151M 133M 237M 14.47B 265M 1.8B 667M 6.03B 625M 613M 25.52B | P/E ratio 2024 * |
-2.12x | P/E ratio 2025 * | -1.9x |
---|---|---|---|---|---|
Enterprise value | 167M 160M 151M 133M 237M 14.47B 265M 1.8B 667M 6.03B 625M 613M 25.52B | EV / Sales 2024 * |
-
| EV / Sales 2025 * | 227x |
Free-Float |
60.71% | Yield 2024 * |
-
| Yield 2025 * | - |
1 day | +3.88% | ||
1 week | -17.67% | ||
Current month | -11.70% | ||
1 month | -2.72% | ||
3 months | -32.41% | ||
6 months | -26.07% | ||
Current year | -10.96% |







Director | Title | Age | Since |
---|---|---|---|
Kristina Masson
COO | Chief Operating Officer | 45 | 2018-02-28 |
Chief Executive Officer | 63 | 2018-03-31 | |
Director of Finance/CFO | 54 | 2022-03-31 |
Manager | Title | Age | Since |
---|---|---|---|
Chairman | 63 | 2018-03-31 | |
Kristina Masson
BRD | Director/Board Member | 45 | 2018-02-28 |
Sharon Shacham
BRD | Director/Board Member | 54 | 2020-09-30 |
Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
---|---|---|---|---|---|---|
+3.88% | -17.67% | +47.25% | - | 167M | ||
+0.05% | -1.16% | +29.01% | -1.03% | 47.75B | ||
-0.89% | -6.63% | -8.93% | -19.74% | 34.52B | ||
-0.45% | -1.71% | -0.38% | +22.57% | 26.11B | ||
-0.08% | +4.72% | +73.31% | +81.97% | 16.54B | ||
-2.09% | -6.79% | -33.62% | -30.17% | 15.08B | ||
+4.54% | -5.03% | -62.61% | -80.21% | 12.28B | ||
+13.36% | +28.87% | - | - | 13.19B | ||
-0.99% | -10.99% | -1.11% | -36.19% | 10.56B | ||
+1.77% | -5.14% | -5.96% | +95.77% | 10.43B | ||
Average | +0.71% | -2.21% | +4.11% | +4.12% | 18.66B | |
Weighted average by Cap. | +0.05% | -1.34% | +5.41% | +2.26% |
2024 * | 2025 * | |
---|---|---|
Net sales | - | 736K 704K 665K 587K 1.05M 63.79M 1.17M 7.92M 2.94M 26.56M 2.76M 2.7M 113M |
Net income | -81.62M -78.15M -73.82M -65.1M -116M -7.08B -130M -879M -326M -2.95B -306M -300M -12.48B | -109M -104M -98.25M -86.64M -154M -9.42B -172M -1.17B -434M -3.92B -407M -399M -16.61B |
Net Debt | - | - |
Date | Price | Change | Volume |
---|---|---|---|
25-02-13 | 5.360 $ | +3.88% | 16,113 |
25-02-12 | 5.160 $ | +5.09% | 35,103 |
25-02-11 | 4.910 $ | -12.63% | 79,290 |
25-02-10 | 5.620 $ | -6.64% | 26,877 |
25-02-07 | 6.020 $ | -7.53% | 31,865 |
Delayed Quote Nasdaq, February 13, 2025 at 04:00 pm EST
More quotes
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- ACRV Stock